Twist Bioscience Corp (NASDAQ:TWST) CTO Bill Peck sold 20,447 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $28.43, for a total value of $581,308.21. Following the sale, the chief technology officer now directly owns 711,839 shares in the company, valued at approximately $20,237,582.77. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of NASDAQ:TWST traded up $0.69 during trading on Friday, hitting $28.57. 184,609 shares of the stock were exchanged, compared to its average volume of 165,264. The company has a fifty day moving average price of $29.84 and a two-hundred day moving average price of $26.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.18 and a quick ratio of 6.96. Twist Bioscience Corp has a 12-month low of $12.38 and a 12-month high of $35.95.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.09). The firm had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $12.51 million. Twist Bioscience had a negative return on equity of 168.45% and a negative net margin of 204.63%. As a group, equities analysts forecast that Twist Bioscience Corp will post -3.8 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Elkfork Partners LLC raised its position in shares of Twist Bioscience by 100.0% during the 2nd quarter. Elkfork Partners LLC now owns 924 shares of the company’s stock worth $27,000 after purchasing an additional 462 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in shares of Twist Bioscience by 100.0% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,176 shares of the company’s stock worth $34,000 after purchasing an additional 588 shares during the last quarter. Glen Harbor Capital Management LLC raised its position in shares of Twist Bioscience by 100.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,428 shares of the company’s stock worth $41,000 after purchasing an additional 714 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Twist Bioscience by 536.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,484 shares of the company’s stock worth $43,000 after purchasing an additional 1,251 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Twist Bioscience by 87,550.0% during the 2nd quarter. Bank of Montreal Can now owns 1,753 shares of the company’s stock worth $51,000 after purchasing an additional 1,751 shares during the last quarter. Hedge funds and other institutional investors own 29.47% of the company’s stock.

TWST has been the topic of several research analyst reports. Evercore ISI initiated coverage on Twist Bioscience in a research note on Friday, May 31st. They set an “outperform” rating and a $26.66 price target on the stock. ValuEngine raised Twist Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $26.55.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading: Dead Cat Bounce

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.